This study focuses on Autosomal Dominant Polycystic Kidney Disease (ADPKD), a genetic condition where fluid-filled cysts develop in the kidneys, causing them to enlarge and potentially lose function over time. The study aims to evaluate a new medication called ABBV-CLS-628, which is given through intravenous administration, along with a placebo to determine if the treatment is safe and effective for adults with this condition.
The study medication ABBV-CLS-628 is a type of monoclonal antibody, which is a protein designed to work with the body’s immune system. During the study, participants will receive either the study medication or a placebo through an injection into a vein. The treatment period will last approximately 96 weeks, during which the size of the kidneys and their function will be monitored.
Throughout the study, various measurements will be taken to track changes in kidney size using MRI scans and to monitor kidney function. The study will involve regular visits to evaluate how well the treatment is working and to check for any potential side effects. Participants will be randomly assigned to either receive the actual medication or the placebo, and neither the participants nor the study doctors will know which treatment is being given.
Belgium 
France 
Germany 
Italy 
Portugal 
Spain 
The Netherlands 
